Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Cancer, Papillary 2Carcinoma, Non-Small-Cell Lung 2Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Sexual Dysfunction, Physiological 1Neoplasms 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Carcinoma, Medullary 1Cachexia-Anorexia Syndrome 1Breast Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenocarcinoma, Follicular 1

Interventions

Iodine-131 5lenvatinib 3X-Rays 3Thyrotropin Alfa 3Magnetic Resonance Spectroscopy 3trametinib 2dabrafenib 2Sunitinib 2Specimen Handling 2Interviews as Topic 2vandetanib 1tremelimumab 1spartalizumab 1selpercatinib 1pembrolizumab 1pazopanib 1durvalumab 1cobimetinib 1cabozantinib 1Vemurafenib 1Thyrotropin 1Thalidomide 1Surgical Procedures, Operative 1Sorafenib 1Sodium Iodide 1Semaxinib 1Photons 1Photochemotherapy 1Phantoms, Imaging 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Follicular × selpercatinib × Clear all
NCT05668962 2024-12-12

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Massachusetts General Hospital

Phase 2 Recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡